Solubility enhancement strategies play a vital role in formulating effective drug products that ensure optimal absorption, bioavailability, and therapeutic outcomes. A comprehensive understanding of aqueous solubility is crucial for the successful development of oral solid formulations with improved therapeutic outcomes. Various approaches are applied in formulation development for solubility enhancement of poorly aqueous soluble drugs in which the development of the liquisolid compact is a promising approach for improving the solubility, dissolution and bioavailability of poorly soluble drugs. With their versatility and potential benefits, they have gained attention as a valuable tool in the formulation of oral solid dosage forms. Furthermore, liquisolid compacts can be conveniently compressed into tablets or filled into capsules, making them suitable for oral administration. Considering these advantages, this study aims to enhance the solubility of Telmisartan by developing liquisolid compacts using Polyethylene Glycol (PEG), Microcrystalline Cellulose (MCC), Colloidal Silica and Crosspovidone as excipients. The six formulations were developed with varying excipients concentrations and evaluated for invitro dissolution studies, indicating Telmisartan's aqueous solubility enhancement in the developed compacts. the excipients drug instruction was studied with the FTIR spectra and DSC and XRD were also performed to evaluate changes after formulation development. The drug release profile of the optimized formulation was also compared with the marketed formulation which shows promising results. These findings highlight the potential of liquisolid compacts in enhancing the solubility and dissolution of Telmisartan, contributing to the formulation of effective drug products.